Consensus Q3 2026 revenue is $1.55 million with an EPS of -$0.14, while the stock's $4.14 price remains significantly below the $13.47 analyst target.
The primary focus for investors is clinical data from the OPGx-BEST1 program and progress in the registrational Phase 3 OPGx-LCA5 trial.
Recent clinical updates highlighted encouraging retinal sensitivity improvements, boosting confidence in the company's gene therapy platform for inherited retinal diseases.
Analysts are also closely monitoring the company's cash runway, which is currently expected to support operations into 2029 following recent capital raises and milestone payments.